Skip to content
Qvanteq
  • Home
  • Technology
    • Key benefits
    • Mechanism of Action
    • Publications
  • Products & Services
    • Neurovascular
    • Peripheral
    • Coronary
    • Other Devices
    • Consulting
  • About us
    • Management
    • Board of Directors
    • Investors
  • News & Media
    • 2021
    • 2020
    • 2019
    • Archive
  • Contact
Qvanteq
  • Home
  • Technology
    • Key benefits
    • Mechanism of Action
    • Publications
  • Products & Services
    • Neurovascular
    • Peripheral
    • Coronary
    • Other Devices
    • Consulting
  • About us
    • Management
    • Board of Directors
    • Investors
  • News & Media
    • 2021
    • 2020
    • 2019
    • Archive
  • Contact
Qvanteq
Qvanteq

Category: Archive

8. October 20188. March 20192018, News

In vitro testing capability with human blood

In collaboration with academic institutions, Qvanteq has developed the capability for dynamic testing of any type of cardiovascular device in a blood loop model (Chandler Loop) using fresh whole human blood. This capability is also available for collaborations.

7. February 20187. February 20182018, News

Qvanteq AG ISO 13485 re-certified

Qvanteq completed ISO13485 re-certification under the guidance of the notified body DEKRA.

30. October 20177. February 20182017, News

Financing round completed

Qvanteq AG completed a financing round. It provides the company with sufficient cash to further develop its technology for vascular stents such as intracranial stents and flow diverters.

7. April 20177. February 20182017, News

Qvanteq’s technology in peer-reviewed journals

In vivo data involving Qvanteq’s surface technology was published in the April issue of the journal Eurointervention.

25. September 20167. February 20182016, News

QUEST I FIM study completed

Qvanteq AG today announced that its QUEST I study was completed. The technology has shown safety in humans.

Posts navigation

1 2 … 5 >

Recent News

  • Reduced thrombogenicity of surface-treated Nitinol implants steered by altered protein adsorption
  • Stop the activation of the blood coagulation cascade by your medical device
  • Make any surface antithrombotic
  • Qvanteq is using MedtechVault
  • In-vitro thrombogenicity screening capacity

Qvanteq AG

Technoparkstr. 1, 8005 Zürich, Switzerland
+41 44 500 98 90
info@qvanteq.com

More

  • Meet us
  • Subscribe
  • Contact
  • Disclaimer
Copyright Qvanteq AG